---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-142911"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2026-04-06T23:59:59+00:00"
generated_at: "2026-05-15T07:16:48.460082+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Neurocrine to acquire Soleno for $53.00/share in $2.9B all-cash transaction

## Summary
- Deal price $53.00 per share; total equity value ~$2.9B; Soleno board recommends shareholders tender.
- VYKAT XR generated $190M revenue in 2025, including $92M in Q4 2025; IP expected to extend to mid-2040s.
- Conditions include tender of >50% of shares, HSR clearance, no material adverse effect, and customary representations.
- Termination fee: $95.25M from Soleno under certain circumstances; $141.5M from Neurocrine if antitrust blocks deal.
- Principal stockholders holding ~1.01% of shares have agreed to tender and vote in favor via support agreements.

## SEC filing metadata
- accession: 0001193125-26-142911
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2026-04-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312526142911/0001193125-26-142911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312526142911/d142985d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-142911
- JSON: https://secwatch.observer/filing/0001193125-26-142911.json
- Plain text: https://secwatch.observer/filing/0001193125-26-142911.txt

## Key facts
- Material Agreements
  SOLENO THERAPEUTICS INC entered into Agreement and Plan of Merger with Neurocrine Biosciences, Inc. valued at $53.00 per share cash tender offer for all outstanding common stock; merger consideration of $53.00 (effective 2026-04-05).
  - Action: entry
  - Agreement: merger
  - Counterparty: Neurocrine Biosciences, Inc.
  - Value: $53.00 per share cash tender offer for all outstanding common stock; merger consideration of $53.00
  - Effective: 2026-04-05
  source text: Item 1.01 Entry Into a Material Definitive Agreement. Agreement and Plan of Merger On April 5, 2026, Soleno Therapeutics, Inc. a Delaware corporation (the “Company” or “Soleno”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Neurocrine Biosciences, Inc., a Delaware corporation (“Parent”), and Sigma Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), pursuant to which Parent, through Purchaser, will commence a cash tender offer (the “Offer”) to purchase all of the issued outstanding shares of the common stock, par value $0.001 (the “Shares”), of the Company, at a price per share of $53.00 per share (the “Offer Price”) in cash, without interest, subject to any applicable withholding taxes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312526142911/0001193125-26-142911-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.